Published and ongoing projects
RvD1 liposomes for treating Osteoarthritis
B cell therapies and technologies to deliver them effectively (in progress)
B cell therapies and technologies to deliver them effectively (in progress)
Resolvin D1-loaded liposomes offer a targeted therapy for osteoarthritis by reducing joint inflammation and promoting tissue repair. This approach was tested in both injury-associated and obesity-aggravated osteoarthritis, addressing distinct inflammatory and metabolic factors. The liposomal delivery improves Resolvin D1 stability and bioavailability, offering a promising strategy for joint degeneration.
B cell therapies and technologies to deliver them effectively (in progress)
B cell therapies and technologies to deliver them effectively (in progress)
B cell therapies and technologies to deliver them effectively (in progress)
Cell therapy is gaining momentum and has already received approval for certain cancers. Here, we develop a platform using engineered B cells for therapeutic applications, delivered via bioengineered carriers. This approach supports cell viability, spatial organization, and targeted immune modulation, advancing precision B cell-based therapies for immunological diseases.
Polymer-based drug delivery vehicles for tackling chronic diseases(collaborative)
Precision Without Carriers: Pure Drug Particles in Infectious Disease Treatment (collaborative)
Precision Without Carriers: Pure Drug Particles in Infectious Disease Treatment (collaborative)
Rapamycin-loaded PLGA particles offer a promising strategy for osteoarthritis treatment by enabling sustained drug release and targeted delivery to inflamed joints. This approach reduces cartilage degradation, modulates immune responses, and improves joint health. The study highlights the therapeutic potential of controlled drug delivery systems for chronic degenerative joint diseases like osteoarthritis.
Read published papers here:
Precision Without Carriers: Pure Drug Particles in Infectious Disease Treatment (collaborative)
Precision Without Carriers: Pure Drug Particles in Infectious Disease Treatment (collaborative)
Precision Without Carriers: Pure Drug Particles in Infectious Disease Treatment (collaborative)
Pure drug particles offer a carrier-free strategy for treating Mycobacterium tuberculosis, enhancing drug loading and minimizing excipient-related toxicity. This approach improves bioavailability, enables sustained release, and targets intracellular pathogens effectively. Our study demonstrates the potential of pure drug particle formulations to advance tuberculosis therapy through simplified, potent, and scalable drug delivery.